| abstract |
Antibody variants for therapeutic use involving trogocytosis-mediated reduction of CD38 on CD38-expressing immunosuppressive cells; particularly CD38 antibody variants comprising one or more mutations in the Fc region, such a mutation in one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein the amino 5 acid residues are numbered according to the EU index. |